$910 Million is the total value of Casdin Capital, LLC's 29 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FATE | FATE THERAPEUTICS INC | $44,804,000 | +36.9% | 2,550,000 | 0.0% | 4.92% | -12.1% | |
| BLFS | BIOLIFE SOLUTIONS INC | $43,447,000 | +48.7% | 2,428,571 | 0.0% | 4.77% | -4.5% | |
| CDXS | CODEXIS INC | $41,573,000 | +22.9% | 2,025,000 | 0.0% | 4.57% | -21.1% | |
| VYGR | VOYAGER THERAPEUTICS INC | $21,591,000 | +103.6% | 1,128,075 | 0.0% | 2.37% | +30.8% | |
| ILMN | ILLUMINA INC | $18,641,000 | +3.6% | 60,000 | 0.0% | 2.05% | -33.5% | |
| EDIT | EDITAS MEDICINE INC | $11,736,000 | +7.5% | 480,000 | 0.0% | 1.29% | -31.0% | |
| SGMO | SANGAMO THERAPEUTICS INC | $10,303,000 | -16.9% | 1,080,000 | 0.0% | 1.13% | -46.6% | |
| FIXX | HOMOLOGY MEDICINES INC | $9,706,000 | +24.0% | 350,000 | 0.0% | 1.07% | -20.4% | |
| BGNE | BEIGENE LTDsponsored adr | $9,240,000 | -5.9% | 70,000 | 0.0% | 1.02% | -39.6% | |
| EVH | EVOLENT HEALTH INCcl a | $6,919,000 | -36.9% | 550,000 | 0.0% | 0.76% | -59.5% | |
| CDNA | CAREDX INC | $6,304,000 | +25.4% | 200,000 | 0.0% | 0.69% | -19.5% | |
| DNLI | DENALI THERAPEUTICS INC | $2,322,000 | +12.4% | 100,000 | 0.0% | 0.26% | -27.8% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-22 |
| SC 13D/A | 2024-05-22 |
| 4 | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-15 |
| 4 | 2024-05-02 |
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.